Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Ashley Kirzinger, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention LYMErix, all published on August 7, 2026.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Ashley Kirzinger, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention LYMErix, all published on August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering LYMErix. Shared-story counts are live from our verified record — not editorial picks.
Pfizer-Valneva regulatory submission planned
Pfizer and Valneva announce they intend to file for approval of their Lyme disease vaccine candidate this spring, according to KFF Health News.
LYMErix withdrawn from market
Citing low demand, lawsuits alleging side effects, and mounting public mistrust, the manufacturer pulls the vaccine only three years after launch.
FDA approves LYMErix
SmithKline Beecham (now GSK) receives approval for the first Lyme disease vaccine, aimed at preventing the tick-borne illness.
Pfizer and Valneva’s planned regulatory submission for a new Lyme disease vaccine enters a market haunted by the failure of LYMErix and amplified vaccine skepticism, challenging the blockbuster potential of a shot aimed at 476,000 annual U.S. cases.
Source: sun-sentinel.com · reporterherald.com
LYMErix is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
